Fusion Fuel appoints uranium investor James Passin to board

Fusion Fuel Green PLC (NASDAQ: HTOO) announced its board of directors approved the appointment of James Passin to its board of directors. The appointment coincides with the company's planned acquisition of a controlling interest in Royal Uranium Inc.

Passin brings more than 20 years of uranium-focused investing experience to Fusion Fuel's board. He previously served as a manager at Firebird Management LLC, where he directed and managed a resource portfolio exceeding $1 billion. At Firebird Global Fund, Passin established uranium exploration and mining as a core focus in 2000 when uranium prices were below $8 per pound.

The company is pursuing a uranium royalty strategy designed to provide exposure to uranium price appreciation and project advancement without direct mine development costs. Through its planned Royal Uranium acquisition, Fusion Fuel seeks to build a diversified uranium royalty platform with exposure to projects across multiple jurisdictions, including Canada's Athabasca Basin.

The Royal Uranium portfolio includes royalty interests associated with projects operated by established uranium industry participants, including Cameco Corporation, Denison Mines Corp., Orano SA, Uranium Energy Corp., and IsoEnergy Ltd.

"James brings exactly the kind of uranium-market experience and cycle-tested judgment that we believe is valuable as Fusion Fuel pursues its uranium royalty strategy," said JP Backwell, Chief Executive Officer of Fusion Fuel.

Passin currently serves as co-founder and CEO of BioVaxys Technology Corp. and as a director of St-Georges Eco-Mining Corp. He holds a Certificate in Corporate Governance from the Mongolian Corporate Governance Institute and is a Chartered Market Technician.

On February 18, 2026, Fusion Fuel entered into a definitive share exchange agreement to acquire a controlling interest in Royal Uranium. The transaction requires approval from the Irish Takeover Panel and Fusion Fuel shareholders. The transaction is expected to close in the first half of 2026.

You May Also Be Interested In

• Karman Line Acquisition closes $200M IPO on Nasdaq
• Aurora Cannabis acquires two UK pharma firms for £2.1 million
• Edesa Biotech prices $25M public offering on Nasdaq